EQS-News: Capital Markets Day 2023: BRAIN Biotech AG to build an international multi-niche enzyme and food ingredients champion

Capital Markets Day 2023: BRAIN Biotech AG to build an international multi-niche enzyme and food ingredients champion

• Strategy: building a successful international multi-niche enzyme and food ingredients champion
• Performance made visible: new organizational setup
• Incubator: Akribion Genomics to focus on opportunities in therapeutics
• Upgraded new ambitious midterm targets 

Zwingenberg, Germany, 27 February 2023 BRAIN Biotech AG, a leading provider of integrated solutions for the biologization of industry, has today at its fourth Capital Markets Day (CMD) informed investors about its future strategy. The company sees significant opportunities in the biotransformation of the economy and is well positioned to benefit from strong global sustainability initiatives in the areas of health, nutrition and the environment.

Creating an international multi-niche enzyme and food ingredients champion builds the core of BRAIN Biotechs future growth strategy. The enzyme activities of the group will focus on food, beverage and healthcare. Nestled in strong scientific roots BRAIN Biotech services the megatrends for better and healthier foods, sustainable industrialization, minimizing pollutants from industrial processes as well as improving health.

Adriaan Moelker, CEO of BRAIN Biotech AG, says: "Over the last three years we have prepared the ground by structural changes to our company portfolio, technology additions, cultural change and people management. Now we have a solid base to build out our strategy of profitable growth with the aim to build an international multi-niche enzyme champion. BRAINs enzyme expertise starts with exceptional scientists and extends into application knowhow in multiple niches with the ability to manufacture in-house at large scale. We are a solutions provider of choice for our customers along the entire value chain. In addition, we will realize significant economic opportunities from our incubator pipeline. I am also happy to announce, that I have agreed with the supervisory board of BRAIN Biotech to extend my contract as a CEO for an additional three years. This will give me the opportunity to execute on our ambitious strategic plans jointly with the entire management team and the BRAIN Group employees.

New Organizational Setup

With its 6M reporting BRAIN Biotech will move to a new three-pillar reporting structure. This will give shareholders an increased transparency and visibility to the operational development of the Group in the segments BioProducts, BioScience and BioIncubator. The BioScience segment represents the activities for bespoke customer solutions in contract research. The BioProducts segment bundles all product related activities of the Group for application-based fermentation and formulation with a focus on food and beverages. This includes the large scale fermentation capacities at subsidiary Biocatalysts. Rod Sears Black, currently MD of Biocatalysts Ltd., will also lead the Group´s combined BioProducts segment as a managing director. The BioIncubator contains BRAIN Biotechs breakthrough discovery projects and the product pipeline to build the future in biotech, including Akribion Genomics.

Michael Schneiders, CFO of BRAIN Biotech AG, states: "During the last months we have worked hard to significantly reduce the complexity of our group structure. This will help to further increase synergy potential and reduce costs. Our new reporting structure offers improved transparency to all of our stakeholders, aligns the internal organization with external reporting and simplifies our equity story for new investors. In addition, with the new structure we will create increased flexibility in group financing and portfolio management. This goes hand in hand with our ambitious strategic and financial targets.

Akribion Genomics: application development beyond BRAIN Biotech´s core activities

Akribion Genomics will increasingly focus on therapeutic applications, including applications in oncology. The mode of action of the nucleases selected for this purpose allows both the targeted cell enrichment and depletion by selective disruption. The increased focus of Akribion Genomics on therapeutic applications further supports BRAIN Biotechs intention to spin-out this proprietary genome-editing technology into the separate legal entity. This will allow a better development of applications which go beyond the current core activities of BRAIN Group and to attract additional funding for accelerated growth. BRAIN Biotech will continue to employ its so-called Gediting platform for the benefit of Group customers also in industrial applications.

Upgraded new ambitious midterm targets

BRAIN Biotech has announced ambitious new midterm targets. Excluding the activities of Akribion Genomics the Group aims to roughly double group sales to 100 million by strong organic growth and selected bolt-on acquisitions. The adjusted EBITDA margin is aimed at 15% (+/- 5PP). The previous mid-term growth guidance is now incorporated in the new target as an intermediate step.

Presentations on the CMD 2023 will be found on the BRAIN Biotech website:

https://www.brain-biotech.com/investors/capital-markets-day

About BRAIN

BRAIN Biotech AG is a leading European specialist in industrial biotechnology with a focus on nutrition, health and the environment. As a technology and solution provider, the company supports the biologization of industry with biobased products and processes. From contract research and development with industrial partners to the development of own disruptive incubator projects and customized enzyme products: BRAIN's broad, innovative biotech know-how and its agile teams are the key to its success.

BRAIN Biotech AG is the parent company of the international BRAIN Group, which distributes B2B specialty products, including enzymes and bioactive natural products. The BRAIN Group has its own fermentation or production facilities in continental Europe, the UK and the USA, which, together with the associated biotechnological production know-how, complete the value chain within the Group.

As a participant in the United Nations Global Compact, BRAIN Biotech AG is committed to aligning its strategies and activities with universal principles on human rights, labor, the environment and anti-corruption, and to actively promote common social goals. BRAIN Biotech´s products and services directly target at least five of the UN SDGs.

Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).

Contact Investor Relations
Martina Schuster
Investor Relations
Phone: +49 6251 9331-69
Email: ms@brain-biotech.com

Contact Media
Dr. Stephanie Konle
PR & Corporate Communications
Phone: +49 6251 9331-70
Email: stk@brain-biotech.com

Follow @BRAINbiotech on Twitter (https://twitter.com/BRAINbiotech) and @BRAIN Biotech AG on LinkedIn (https://www.linkedin.com/company/brainbiotech)

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management.

Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance by, and future developments at, BRAIN Biotech AG and the BRAIN Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors.

BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.